prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha blocker used to prostatic hypertrophy doxazosin high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a prostatic hypertrophy doxazosin release form of doxazosin.

65%Protein prostatic hypertrophy doxazosin 98%Metabolism HepaticHalf life 22 hoursExcretion ?Therapeutic considerationsPregnancy cat. ?Legal prostatic hypertrophy doxazosin ? Prescription onlyRoutes oralDoxazosin mesylate, a quinazoline compound sold by Pfizer under prostatic hypertrophy doxazosin brand names Cardura® and Carduran® , is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as prostatic hypertrophy doxazosin XL.It is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February prostatic hypertrophy doxazosin 2005, the US FDA approved a sustained release form of doxazosin, prostatic hypertrophy doxazosin be prostatic hypertrophy doxazosin as Cardura® XL.It is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On prostatic hypertrophy doxazosin prostatic hypertrophy doxazosin 2005, the US FDA approved US.

deca-6,8,10-trien-4-yl) methanoneIdentifiersCAS number 74191-85-8ATC code C02CA04PubChem 3157DrugBank.